ArticleMarine drugs2014
Phlorotannins from Alaskan seaweed inhibit carbolytic enzyme activity.
Article in Marine drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- Effect of brown seaweed on plasma glucose in healthy, at-risk, and type 2 diabetic individuals: systematic review and meta-analysis.Nutrition reviews · 2022Pooled it
- Brown Seaweeds and Their Bioactive Compounds in Type 2 Diabetes: Mechanisms Underlying Metabolic Regulation.International journal of molecular sciences · 2026Review
- Anti-Diabetic Potential ofCurrent issues in molecular biology · 2023Article
- Antioxidant and Antidiabetic Properties of Phlorotannins fromMolecules (Basel, Switzerland) · 2023Review
- Uses of Papaya Leaf and Seaweed Supplementations for Controlling Glucose Homeostasis in Diabetes.International journal of molecular sciences · 2023Review
- Separation of flavonoids with significant biological activity fromRSC advances · 2023Article
- Hypoglycaemic Molecules for the Management of Diabetes Mellitus from Marine Sources.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- Overview of Phlorotannins' Constituents in Fucales.Marine drugs · 2022Review
- Apple Fibers as Carriers of Blackberry Juice Polyphenols: Development of Natural Functional Food Additives.Molecules (Basel, Switzerland) · 2022Article
- Multifunctional Gelatin/Chitosan Electrospun Wound Dressing Dopped withPharmaceutics · 2021Article
- Polyphenols from Brown Seaweeds (Ochrophyta, Phaeophyceae): Phlorotannins in the Pursuit of Natural Alternatives to Tackle Neurodegeneration.Marine drugs · 2020Review
- Bioactive Properties of Marine Phenolics.Marine drugs · 2020Review
- Brown Seaweeds for the Management of Metabolic Syndrome and Associated Diseases.Molecules (Basel, Switzerland) · 2020Review
- The Evolution Road of Seaweed Aquaculture: Cultivation Technologies and the Industry 4.0.International journal of environmental research and public health · 2020Review
- Seaweed Phenolics: From Extraction to Applications.Marine drugs · 2020Review
- Crystallographic analysis of Eisenia hydrolysis-enhancing protein using a long wavelength for native-SAD phasing.Acta crystallographica. Section F, Structural biology communications · 2020Article
- The Quest for Phenolic Compounds from Macroalgae: A Review of Extraction and Identification Methodologies.Biomolecules · 2019Review
- Optimization of Phlorotannins Extraction fromMarine drugs · 2019Article
- Nutraceutical Potential of Five Mexican Brown Seaweeds.BioMed research international · 2019Article
- Screening ofInternational journal of molecular sciences · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Global incidence of type 2 diabetes has escalated over the past few decades, necessitating a continued search for natural sources of enzyme inhibitors to offset postprandial hyperglycemia. The objective of this study was to evaluate coastal Alaskan seaweed inhibition of α-glucosidase and α-amylase, two carbolytic enzymes involved in serum glucose regulation. Of the six species initially screened, the brown seaweeds Fucus distichus and Alaria marginata possessed the strongest inhibitory effects. F. distichus fractions were potent mixed-mode inhibitors of α-glucosidase and α-amylase, with IC50 values of 0.89 and 13.9 μg/mL, respectively; significantly more efficacious than the pharmaceutical acarbose (IC50 of 112.0 and 137.8 μg/mL, respectively). The activity of F. distichus fractions was associated with phlorotannin oligomers. Normal-phase liquid chromatography-mass spectrometry (NPLC-MS) was employed to characterize individual oligomers. Accurate masses and fragmentation patterns confirmed the presence of fucophloroethol structures with degrees of polymerization from 3 to 18 monomer units. These findings suggest that coastal Alaskan seaweeds are sources of α-glucosidase and α-amylase inhibitory phlorotannins, and thus have potential to limit the release of sugar from carbohydrates and thus alleviate postprandial hyperglycemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.